Topic

Articles

Immutep was granted a Chinese patent for LAG525, a LAG-3 antagonist antibody, under evaluation for cancer treatment.

Immutep Granted a Chinese Patent for LAG-3 Antagonist Antibody

BlueAllele has been granted a US patent for its advanced gene-editing technology, PALIDON, which is compatible with existing gene editing nucleases and delivery systems.

Patent Office Grants BlueAllele Patent for Advanced Gene Editing Technology

Immodulon has received an indication of allowability from the European Patent Office for the claims in its patent application relating to its lead drug candidate.

Immodulon Gains Allowability of Claims for Key European Patent Application

Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.

Salipro Biotech Gains European Patent for Novel Method of Membrane Protein Extraction and Library Generation

Scientists at the company learned that deagglomeration techniques lose efficacy through equipment wear over time and developed a tactic that makes up for the wear and prepares an ideal sample for each particle size test. 

Hovione Technology Granted Patent for Deagglomeration Method

More work is needed to educate businesses on the value of innovation and the availability of funding.

Continued Innovation is Key for COVID-19 Recovery

Editor of Pharmaceutical Technology Europe

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Balancing Innovation Protection and Affordability

Diurnal Group has been granted a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office.

Diurnal Receives Patent Grant from European Patent Office

Kevin E. Noonan, PhD, noonan@mbhb.com, is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Protecting Intellectual Property for COVID-19 Innovations

The register supports cross-functional teams of chemists and biologists in developing non-natural, chemically-modified therapeutics for drug discovery.

Intellectual Property & Patents